The UK has some of the world’s most exciting science, a supportive business environment, a vibrant financial sector and strong companies led by experienced management teams. The UK is building something great – a global bioscience cluster that delivers life-changing treatments for patients in the National Health Service, rewarding and high-paying R&D and manufacturing jobs for people across the UK, and sustainable long-term economic growth for the country. The UK is recognised as a world leader in the life sciences, and the sector contributed £30.4bn to the UK economy in 2015 and supported 482,000 jobs, according to a recent report by PwC.

Market Facts

  • UK has the strongest and most robust clinical pipeline in Europe: The number of drug products in clinical development (or in registration with regulators) is higher in the UK than anywhere else in Europe. 
  • UK leads Europe in venture capital funding and is gaining on US clusters: UK companies received £680 million in venture capital in 2016, more than a third of the total venture capital raised in Europe and more than any other European country.

UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.

Association’s resources

  • Engineering Biology Explained

    Engineering Biology Explained: A guide to engineering biology and UK excellence in the field.

    See Publication
  • Confident Capital: Backing UK Biotech

    This Report released by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017.

    See Publication
  • Cell and Gene Therapy Explained

    Cell and Gene Therapy Explained: A guide to cell and gene therapy and UK excellence in the field.

    See Publication
  • Antimicrobial Resistance Explained: A Guide to Antimicrobial Resistance and How UK Excellence is Helping Tackle this Global Ghallenge

    Antibiotics are a triumph of modern medicine. Alexander Fleming’s famously serendipitous discovery of penicillin during the 1920s led to one of the most effective treatments for bacterial infections, still in use today. But the success of penicillin and many other antibiotics developed since has created an entirely new, arguably even bigger healthcare challenge, that of antimicrobial resistance (AMR).

    Bacteria have learned to out-smart antimicrobial molecules and have developed resistance. Bacteria reproduce and evolve far faster than humans and most animals, and they can share helpful DNA easily among each other, not just with their offspring.

    This document explains more on AMR and what BIA member companies are doing to tackle it.

    See Publication
  • A Vision for the UK Life Sciences Sector in 2025

    This report provides a roadmap for the growth of the UK biotechnology industry.

    See Publication
  • A Guide to Genomics

    Genomics Explained: A guide to genomics and UK excellence in the field.

    See Publication